BeyondSpring Inc. (BYSI)
Automate Your Wheel Strategy on BYSI
With Tiblio's Option Bot, you can configure your own wheel strategy including BYSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BYSI
- Rev/Share -0.0109
- Book/Share -0.3142
- PB -3.5889
- Debt/Equity -0.0193
- CurrentRatio 2.4892
- ROIC -0.2582
- MktCap 101597076.0
- FreeCF/Share -0.512
- PFCF -4.9221
- PE 495.5957
- Debt/Assets 0.0147
- DivYield 0
- ROE -0.0067
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, on May 31st, 2025 in Chicago, IL.
Read More
About BeyondSpring Inc. (BYSI)
- IPO Date 2017-03-09
- Website https://www.beyondspringpharma.com
- Industry Biotechnology
- CEO Lan Huang
- Employees 40